The Calculated Genetic Barrier for Antiretroviral Drug Resistance Substitutions Is Largely Similar for Different HIV-1 Subtypes
about
Sequencing paediatric antiretroviral therapy in the context of a public health approachDifferential drug resistance acquisition in HIV-1 of subtypes B and CHCV genotypes are differently prone to the development of resistance to linear and macrocyclic protease inhibitorsLong-lasting protection of activity of nucleoside reverse transcriptase inhibitors and protease inhibitors (PIs) by boosted PI containing regimensThe individualized genetic barrier predicts treatment response in a large cohort of HIV-1 infected patientsDifferent frequencies of drug resistance mutations among HIV-1 subtypes circulating in China: a comprehensive studyHow Much Do We Know about Drug Resistance Due to PrEP Use? Analysis of Experts' Opinion and Its Influence on the Projected Public Health ImpactGenetic Barrier to Direct Acting Antivirals in HCV Sequences Deposited in the European DatabankHIV-1 Genetic Variability and Clinical ImplicationsHIV-1 genetic variation and drug resistance development.Getting to 90-90-90 in paediatric HIV: What is needed?Impact of HIV type 1 subtype on drug resistance mutations in Nigerian patients failing first-line therapyGenetic characterization and antiretroviral resistance mutations among treatment-naive HIV-infected individuals in Jiaxing, China.Transmitted drug resistance in nonsubtype B HIV-1 infection.Estimating the individualized HIV-1 genetic barrier to resistance using a nelfinavir fitness landscapeThe K65R mutation in HIV-1 reverse transcriptase: genetic barriers, resistance profile and clinical implications.Naturally occurring variability in the envelope glycoprotein of HIV-1 and development of cell entry inhibitors.Increase in transmitted resistance to non-nucleoside reverse transcriptase inhibitors among newly diagnosed HIV-1 infections in Europe.HIV Genetic Diversity and Drug Resistance.Two Distinct Hepatitis C Virus Genotype 1a Clades Have Different Geographical Distribution and Association With Natural Resistance to NS3 Protease Inhibitors.Comprehensive Screening for Naturally Occurring Hepatitis C Virus Resistance to Direct-Acting Antivirals in the NS3, NS5A, and NS5B Genes in Worldwide Isolates of Viral Genotypes 1 to 6Human immunodeficiency virus type 1 subtype distribution in the worldwide epidemic: pathogenetic and therapeutic implications.Comparative analysis of drug resistance among B and the most prevalent non-B HIV type 1 subtypes (C, F, and CRF02_AG) in Italy.Characterization of two HIV-1 infectors during initial antiretroviral treatment, and the emergence of phenotypic resistance in reverse transcriptase-associated mutation patterns.Viral Genetic Diversity and Polymorphisms in a Cohort of HIV-1-Infected Patients Eligible for Initiation of Antiretroviral Therapy in Abuja, Nigeria.HIV-1 subtype distribution and its demographic determinants in newly diagnosed patients in Europe suggest highly compartmentalized epidemics.Bayesian network analyses of resistance pathways against efavirenz and nevirapine.Prevalence and determinants of transmitted antiretroviral drug resistance in HIV-1 infection.HIV-1 drug resistance mutations: an updated framework for the second decade of HAARTPhylogenetic inferences on HIV-1 transmission: implications for the design of prevention and treatment interventionsClinical significance of HIV reverse-transcriptase inhibitor-resistance mutations.HIV testing and antiretroviral treatment strategies for prevention of HIV infection: impact on antiretroviral drug resistance.NS3 protease polymorphisms and genetic barrier to drug resistance of distinct hepatitis C virus genotypes from worldwide treatment-naïve subjects.Hepatitis C virus genetic variability and the presence of NS5B resistance-associated mutations as natural polymorphisms in selected genotypes could affect the response to NS5B inhibitors.Second-line HIV Treatment in Ugandan Children: Favorable Outcomes and No Protease Inhibitor Resistance.Increasing the use of second-line therapy is a cost-effective approach to prevent the spread of drug-resistant HIV: a mathematical modelling study.Prevalence of drug resistance mutations in HAART patients infected with HIV-1 CRF06_cpx in Estonia.HIV integrase variability and genetic barrier in antiretroviral naïve and experienced patients.Early selection of resistance-associated mutations in HIV-1 RT C-terminal domains across different subtypes: role of the genetic barrier to resistance.Subtype diversity associated with the development of HIV-1 resistance to integrase inhibitors.
P2860
Q26774261-17834E17-8FC1-4530-9648-1E5162F8DF11Q28469273-46118D95-E391-4155-ADEF-C122A25A08A5Q28481038-D7D5A8E6-A331-4F3A-8F72-4198969F342FQ28485321-3AAFF1E4-1282-4CE2-9CCA-8CEEAA033DAEQ28536153-4D8AC432-2E2C-403B-B56E-4CA21565B8B2Q28541365-D99E18E1-DF95-44DF-8301-5A00051108DFQ28552455-334CE063-D46E-4DDC-AE9D-E9DA95D7BE9DQ28553430-3B8FB8B8-3275-4F21-8460-82EF8D5FD364Q30352010-BB21A1F3-A169-4970-BB89-25E4EED58FDFQ30354857-FFF55026-058D-462F-BD61-63C89D501DF9Q30385352-20198FFF-C22C-4C74-A4DA-7AAB4BE6FC13Q30395110-8365CFCB-4178-463D-9E99-C02F3DAFF57DQ33566910-399B3A8E-23CA-42B2-A4DE-559F75765F97Q33567164-B7319529-3281-48C9-8BB8-8EF161761D93Q33648513-6F60F11B-4445-495B-B3FE-68D70100A2F8Q33681279-8783E476-7AD7-4B34-BB4A-DC2FDF44B371Q33733243-89FC8AC9-04DD-4D74-A7FB-4046A102007BQ34469240-4EABF8A8-BE97-408B-9A11-A2E031F4528BQ35260590-EC709CBC-7ADE-4443-9556-413436077372Q35880497-E1E23337-DE34-46D5-A864-71472ED37390Q35917596-968CD189-4013-4EDF-A76B-BD33B1399E5EQ36099119-0DB95959-E09E-4463-9ED2-FA708F162F18Q36250342-D3B46A37-2EE4-461A-AD46-637B3C4A6DB3Q36292765-CC24010C-0DF1-4256-934D-0B3ED28AD5F7Q36418462-0E0C70E6-5730-4E43-9563-93AEE47D6910Q36588672-7EA56DAF-6B42-4061-8853-B449AA844504Q36677558-1471AF40-FCF3-4429-A0BD-00416E4CA24CQ36798007-7B6ED538-38CA-40B6-AA80-024CE4D3DD08Q36900010-04A0CFC2-4281-46BA-B1A3-58EFC0772EEBQ37206422-757E3BEA-04B6-44AA-B53C-C00962E8EEA7Q37859395-F31F50E7-5095-45C5-AEDF-C1C35852097EQ37935116-606DB9BB-3C00-4BE4-82B5-3BD572927109Q38699377-72CAF6BA-E747-4AE0-8E2F-2C1324537696Q38849307-96900018-2450-4BA6-9056-21EFC54C893BQ38853002-3EF3416D-8110-4B4E-987A-3FB02320162AQ38860584-CA14C103-82B5-4360-BF66-0FFCA17912E5Q41042591-C370465E-A81A-4449-BD17-3FDA7E85456FQ42094831-8A09CC45-8A68-45F1-8AA6-83B0920F8EF1Q42211133-925E7E40-E86F-4083-9D7B-F444B1CD6441Q46307515-D9AE1CA4-0C8A-4EB6-98F9-1CE3ED648A32
P2860
The Calculated Genetic Barrier for Antiretroviral Drug Resistance Substitutions Is Largely Similar for Different HIV-1 Subtypes
description
article
@en
im März 2006 veröffentlichter wissenschaftlicher Artikel
@de
wetenschappelijk artikel
@nl
наукова стаття, опублікована в березні 2006
@uk
name
The Calculated Genetic Barrier ...... r for Different HIV-1 Subtypes
@en
The Calculated Genetic Barrier ...... r for Different HIV-1 Subtypes
@nl
type
label
The Calculated Genetic Barrier ...... r for Different HIV-1 Subtypes
@en
The Calculated Genetic Barrier ...... r for Different HIV-1 Subtypes
@nl
prefLabel
The Calculated Genetic Barrier ...... r for Different HIV-1 Subtypes
@en
The Calculated Genetic Barrier ...... r for Different HIV-1 Subtypes
@nl
P2093
P50
P1476
The Calculated Genetic Barrier ...... r for Different HIV-1 Subtypes
@en
P2093
Andrzej Horban
Andy Hoepelman
Angelos Hatzakis
Annemarie M. J. Wensing
Birgitta ??sj??
Carmen de Mendoza
Charles A. B. Boucher
Claudia K??cherer
Claus Nielsen
Clive Loveday
P304
P356
10.1097/01.QAI.0000209899.05126.E4
P407
P50
P577
2006-03-01T00:00:00Z